Biological evaluation of recombinant human erythropoietin in pharmaceutical products

Abstract

The potencies of mammalian cell-derived recombinant human erythropoietin pharmaceutical preparations, from a total of five manufacturers, were assessed by in vivo bioassay using standardized protocols. Eight-week-old normocythemic mice received a single subcutaneous injection followed by blood sampling 96 h later or multiple daily injections with blood sampling 24 h after the last injection. Reticulocyte counting by microscopic examination was employed as the endpoint using the brilliant cresyl blue or selective hemolysis methods, together with automated flow cytometry. Different injection schedules were investigated and dose-response curves for the European Pharmacopoeia Biological Reference Preparation of erythropoietin were compared. Manual and automated methods of reticulocyte counting were correlated with respect to assay validity and precision. Using 8 mice per treatment group, intra-assay precision determined for all of the assays in the study showed coefficients of variation of 12.1-28.4% for the brilliant cresyl blue method, 14.1-30.8% for the selective hemolysis method and 8.5-19.7% for the flow cytometry method. Applying the single injection protocol, a combination of at least two independent assays was required to achieve the precision potency and confidence limits indicated by the manufacturers, while the multiple daily injection protocol yielded the same acceptable results within a single assay. Although the latter protocol using flow cytometry for reticulocyte counting gave more precise and reproducible results (intra-assay coefficients of variation: 5.9-14.2%), the well-characterized manual methods provide equally valid alternatives for the quality control of recombinant human erythropoietin therapeutic products. Correspondence

Selective functional inhibition of JAK‐3 is sufficient for efficacy in collagen‐induced arthritis in mice

“…In the second functional model, EPO, a potent erythropoietic agent that signals exclusively through the JAK-2 pathway (9), was used to induce reticulocytosis in the peripheral blood of mice (32). The effect of the JAK-3 inhibitors, WYE-151650 and CP-690,550, on EPO-induced reticulocytosis was assessed as a measure of JAK-2 selectivity in vivo.…”

Lessons learned from biosimilar epoetins and insulins

“…26,27 ) Different commercially produced follow-on epoetin alpha products share an identical amino acid sequence, but differ greatly in their glycosylation profiles, and hence in their biological activity. 28 These differences can be dramatic: one study using isoelectric focusing to compare 11 epoetin alpha products from manufacturers in Korea, Argentina, China and India found that their molecular weights varied substantially (figure 3). 29 Additional studies have reported that epoetins from different sources vary widely in biological activity from 70% to over 200% of their own stated specifications.…”

Biosimilars: recent developments

“…Since the manufacturers of biopharmaceuticals are not obliged to disclose their manufacturing procedures, biosimilars manufacturers have to work out their own manufacturing protocols based upon the final product. When analytic and clinical evaluations of EPO biosimilar products currently marketed outside the US and Europe were conducted, it was revealed that the products' composition differed widely, they exhibited interbatch variation, and often did not meet selfdeclared specifications [11,12]. This variation between products underscores the colossal difficulties in replicating biopharmaceutical proteins.…”